QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
NASDAQ:TNXP

Tonix Pharmaceuticals (TNXP) Stock Forecast, Price & News

$1.63
-0.04 (-2.40%)
(As of 05/30/2023 ET)
Compare
Today's Range
$1.62
▼
$1.76
50-Day Range
$1.63
▼
$12.00
52-Week Range
$1.62
▼
$29.94
Volume
394,406 shs
Average Volume
440,829 shs
Market Capitalization
$16.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.63
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Tonix Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,392.3% Upside
$40.63 Price Target
Short Interest
Bearish
6.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Tonix Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($9.56) to ($7.88) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

704th out of 1,009 stocks

Pharmaceutical Preparations Industry

356th out of 494 stocks

See Top Rated MarketRank™ Stocks Here

TNXP stock logo

About Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company headquartered in Chatham, New Jersey. The company was founded in 2007 and then later went public in 2013. Tonix Pharmaceuticals is led by Seth Lederman who has been CEO since co-founding the company. Mr. Lederman was an Associate Professor at Columbia University for more than 2 decades before venturing into the private sector. Tonix Pharmaceuticals is his second venture, the first was bought out after developing an effective treatment for colorectal cancer. The company operates through three facilities located in Massachusetts, Maryland, and Montana.

The two east-coast facilities are the R&D center and the Advanced Development Center while manufacturing is located in Montana. The Maryland facility is rated BSL-2 with some areas rated BSL-3 which allows for the handling of live viruses. The Massachusetts facility is intended to enhance the company’s R&D and analytics capabilities as well as facilitate vaccine production at the clinical trial scale. The Montana facility will support Phase III trials as well as the mass production of approved treatments.

Tonix Pharmaceuticals focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering across a wide spectrum of ailments and treatments. Among them is COVID-19 for which the company has several products in development.

Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The types of diseases the company targets are widely occurring but hard to treat so breakthroughs of any kind could be significant sources of income. The company has several candidates in pre-clinical and clinical trials with two standouts that are on track for FDA approval. Resilient, a treatment for Fibromyalgia, and Prevail, a treatment for long-COVID, entered Phase III and Phase II trials in 2022.

The immunology portfolio includes treatments for organ transplant rejection, autoimmunity, and cancer, and several in this group have shown efficacy against multiple indications. The company’s infectious disease pipeline includes several promising treatments for viruses afflicting the world today. The TNX-80 vaccine is intended to prevent smallpox and monkeypox while TNX-1840 and TNX-1850 are live virus vaccines to fight COVID-19, as will TNX-3500 and TNX-102, which are small molecule antiviral drugs.

Tonix Pharmaceuticals CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction including Resilient, which is in mid-Phase 3 development for the management of fibromyalgia. Other products in the pipeline are TNX-1900 which is in development for the prevention of migraine headaches and TNX-1300 which is designed to treat cocaine intoxication.

Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TNXP Stock News Headlines

May 30, 2023 | finance.yahoo.com
Tonix Pharmaceuticals Announces Presentation at the 2023 BIO International Convention
May 28, 2023 | americanbankingnews.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded to "Sell" by StockNews.com
May 30, 2023 | UNKNOWN (Ad)
Lithium Has Boomed And This American Stock Is Ready..
Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!
May 26, 2023 | finanznachrichten.de
Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 24, 2023 | finance.yahoo.com
Tonix Pharmaceuticals to Present at the June 1st Virtual Investor Summit
May 23, 2023 | finance.yahoo.com
Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative Diseases
May 22, 2023 | finanznachrichten.de
Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)
May 21, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)
May 30, 2023 | UNKNOWN (Ad)
Lithium Has Boomed And This American Stock Is Ready..
Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!
May 17, 2023 | finance.yahoo.com
Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression
May 10, 2023 | americanbankingnews.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS
May 10, 2023 | finanznachrichten.de
Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces 1-for-6.25 Reverse Stock Split
May 9, 2023 | seekingalpha.com
Tonix Pharma falls 30% after announcing another reverse stock split
May 9, 2023 | finance.yahoo.com
Tonix Pharmaceuticals Announces 1-for-6.25 Reverse Stock Split
May 9, 2023 | americanbankingnews.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by StockNews.com
May 5, 2023 | americanbankingnews.com
Brokers Set Expectations for Tonix Pharmaceuticals Holding Corp.'s FY2025 Earnings (NASDAQ:TNXP)
May 4, 2023 | finance.yahoo.com
Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant
May 4, 2023 | americanbankingnews.com
Brokers Offer Predictions for Tonix Pharmaceuticals Holding Corp.'s Q1 2023 Earnings (NASDAQ:TNXP)
April 30, 2023 | americanbankingnews.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Receives New Coverage from Analysts at StockNews.com
April 29, 2023 | americanbankingnews.com
Short Interest in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Decreases By 42.0%
April 21, 2023 | proactiveinvestors.com
Tonix Pharmaceuticals TNX-1500 monoclonal antibody published in American Journal of Transplantation
April 17, 2023 | finance.yahoo.com
Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft Survival
April 13, 2023 | msn.com
Tonix Pharmaceuticals Fast Forwards Its Fibromyalgia, Migraine Studies
April 7, 2023 | marketwatch.com
8-K: Tonix Pharmaceuticals Holding Corp.
April 5, 2023 | markets.businessinsider.com
Noble Financial Reaffirms Their Buy Rating on Tonix Pharma (TNXP)
April 5, 2023 | finance.yahoo.com
Tonix Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2023
April 4, 2023 | msn.com
Tonix Pharma Deprioritizes COVID-19 Related Programs, Pending PTSD Trial
See More Headlines
Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TNXP Company Calendar

Last Earnings
3/13/2023
Today
5/30/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNXP
CUSIP
N/A
CIK
1430306
Web
www.tonixpharma.com
Phone
(862) 799-8599
Fax
212-923-5700
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$40.63
High Stock Price Forecast
$40.63
Low Stock Price Forecast
$40.63
Forecasted Upside/Downside
+2,354.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($18.6875)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-110,220,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-56.31%
Return on Assets
-50.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.40
Quick Ratio
6.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$22.51 per share
Price / Book
0.07

Miscellaneous

Outstanding Shares
10,340,000
Free Float
10,143,000
Market Cap
$17.11 million
Optionable
Optionable
Beta
2.17

Key Executives

  • Seth LedermanSeth Lederman
    Chairman, President & Chief Executive Officer
  • Jessica Edgar Morris
    Chief Operating Officer
  • Bradley Saenger
    Chief Financial Officer & Treasurer
  • Gregory M. Sullivan
    Secretary & Chief Medical Officer
  • Bruce L. Daugherty
    Executive Vice President-Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TNXP Stock - Frequently Asked Questions

Should I buy or sell Tonix Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNXP shares.
View TNXP analyst ratings or view top-rated stocks.

What is Tonix Pharmaceuticals' stock price forecast for 2023?

1 Wall Street analysts have issued 12 month price objectives for Tonix Pharmaceuticals' stock. Their TNXP share price forecasts range from $40.63 to $40.63. On average, they anticipate the company's share price to reach $40.63 in the next year. This suggests a possible upside of 2,354.7% from the stock's current price.
View analysts price targets for TNXP or view top-rated stocks among Wall Street analysts.

How have TNXP shares performed in 2023?

Tonix Pharmaceuticals' stock was trading at $2.4363 on January 1st, 2023. Since then, TNXP stock has decreased by 32.1% and is now trading at $1.6550.
View the best growth stocks for 2023 here.

Are investors shorting Tonix Pharmaceuticals?

Tonix Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 638,800 shares, an increase of 167.6% from the April 30th total of 238,700 shares. Based on an average daily trading volume, of 217,100 shares, the short-interest ratio is presently 2.9 days. Approximately 6.2% of the company's shares are sold short.
View Tonix Pharmaceuticals' Short Interest.

When is Tonix Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our TNXP earnings forecast.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) released its earnings results on Monday, March, 13th. The company reported ($3.50) earnings per share for the quarter, topping the consensus estimate of ($5.38) by $1.88.

When did Tonix Pharmaceuticals' stock split?

Tonix Pharmaceuticals shares reverse split on the morning of Wednesday, May 10th 2023. The 1-6.25 reverse split was announced on Wednesday, May 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 16 shares after the split.

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

Who are Tonix Pharmaceuticals' major shareholders?

Tonix Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.95%), Geode Capital Management LLC (5.16%), JPMorgan Chase & Co. (2.83%), Raymond James & Associates (0.42%), State Street Corp (1.89%) and Acadian Asset Management LLC (0.26%). Insiders that own company stock include Daniel Wintner Goodman, Gregory M Sullivan, James Treco, Margaret Smith Bell and Seth Lederman.
View institutional ownership trends.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $1.66.

How much money does Tonix Pharmaceuticals make?

Tonix Pharmaceuticals (NASDAQ:TNXP) has a market capitalization of $17.11 million. The company earns $-110,220,000.00 in net income (profit) each year or ($18.6875) on an earnings per share basis.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The official website for the company is www.tonixpharma.com. The company can be reached via phone at (862) 799-8599, via email at investor.relations@tonixpharma.com, or via fax at 212-923-5700.

This page (NASDAQ:TNXP) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -